The pr needs one simple edit Next to Remdesivir Add (Gilead Sciences Inc. Nasdaq GILD). This simple change gets their name in the spotlight that's all that matters. If gild refuses that's news, if the trial happens that's news. Right now major media and officials wont talk about leronlimab. CNBC they dont touch it cause it's on the low rent OTC. This pr attaches it to GILD. They should release the pr with gilead nam and ticker in the text then it automatically shows up when searching GILD. Millions search GILD most never heard of cydy
Market Data 
Markets 
AI
